Healthcare stocks haven't gotten a lot of love from investors in recent years. While the market has been strong and the S&P ...

Dow Jones Top Company Headlines at 3 PM ET: Tilray and Cannabis Stocks Fall as Trump Reschedules Marijuana | Instacart ... The president signed an executive order to reschedule marijuana as a ...

The filing comes as Novo fights tooth-and-nail with rival Lilly to regain its footing at the top of the weight loss market.

Good news for people on GLP-1 therapy who hate needles: Trial data out this week shows that an experimental pill developed by ...

Novo Nordisk filed an FDA application for weekly CagriSema after trials showed up to 22.7% weight loss versus placebo.

As of February 2025, the semaglutide injection (Ozempic, Wegovy) shortage was resolved. As a result, compounded semaglutide ...

CagriSema would be the first combo GLP-1 if it’s approved, while orforglipron would be the first GLP-1 pill approved for ...

The drug was as good as a proven GLP-1, giving doctors another potent option for patients with type 2 diabetes and ...

Dow Jones Top Financial Services Headlines at 11 AM ET: Novo Nordisk Files For FDA Approval of Obesity Drug CagriSema | Deerpath ... Wegovy maker Novo Nordisk filed for U.S. FDA approval of CagriSema, ...

Medicare enrollees will save more than 50% on out-of-pocket costs for 10 common prescription drugs under their insurance ...

More GLP-1s aim to enter US market as Novo Nordisk, Eli Lilly, and Pfizer advance obesity treatments with FDA filings and trials.

Participants in a Phase III trial who switched to Eli Lilly’s orforglipron after 72 weeks of treatment with Wegovy or ...